



Global Summit on International Breast Health and Cancer Control:

Improving Breast Health Care through Resource-Stratified Phased Implementation

Financing: Creative Financing Strategies for Cancer Treatment

Richard Sullivan, MD, PhD

Kings College London (United Kingdom)



1. **Cancer care is not ‘cheap’ or ‘cost effective’** e.g. *pancreatic surgery in public sector in India* (Financial Impact of Complex Cancer Surgery in India: A Study of Pancreatic Cancer Journal of Global Oncology 2018 :4, 1-9)

2. **Distributional paradoxes:** lack of equipment, infrastructure in public sector but (over) supply in private sector

3. Non-pharmaceutical technologies are, potentially, a much greater challenge to affordable cancer care BUT recurrent costs for additional **human capital** is being completely ignored

4. Many high income countries have serious problems managing their **debt-to-GDP ratios**; health reforms are failing (Jourmard et al. Health care systems 2010. OECD Working Paper no 769 & Economic outlook 2012)

5. Cultural and structural reforms to healthcare may be beyond **the will or ability** of many governments (Chalkidou et al. Evidenced informed frameworks for cost effective cancer care, etc. Lancet Oncology, 2014, 15:119-131)




KING'S HEALTH PARTNERS

Integrated Cancer Centre

PRICE CONTROL

Supply and Demand side policy

- **Prices outside regulated systems are highly volatile**
- They are higher and this, coupled to ‘irrational’ clinical choices leads to unbalanced, unsustainable costs
- Variety of mechanisms for price control but many countries have neither the technical expertise, systems and / or will to use this



Inefficiencies in Procurement Processes



Low visibility on drug demand leads to under/over utilisation of budget, inadequate service delivery.



Weak contract management practices, leading to failure to hold contractors to agreed service levels.



Inadequate monitoring of stock levels and high lead time leads to **stock-outs of life saving drugs**.

Inefficiencies in Drug Market



Low transparency in drug market leads to **information asymmetry on prices, quality**.



Low volume purchase for critical drugs leads to **procurement at higher prices or delayed shipments**.




Less stringent regulatory mechanisms result in procurement of **substandard quality drugs** or batches.



KING'S HEALTH PARTNERS

Integrated Cancer Centre




COSTS

Recurrent and Capital Patient Impact

Cost of breast cancer treatment in Kenya in 2016


	Percentage of Patients ^a	Public Facility (U.S. \$)	Private Facility (U.S. \$)
Breast Cancer Treatment^b			
Stage I	7	1,340.38	10,914.45
Stage II	35	1,340.38	10,914.45
Stage III (curative approach)	19	1,542.58	11,862.36
Stage III (palliative approach) and Stage IV	40	675.35	8,569.87

Annual Household income though is
272.4 (rural) to 712.20 (urban) USD




Households that use distressed financing for their breast cancer care in India in 2012

55% who used private sector care
40% who used public sector care




Cannot assume same spectrum of costs as you would see in high income settings



- **Cost data from LMIC is VERY poor:** lack of time sensitive studies, lack of **mixed methods**, lack of interest in conducting such studies and lack of funders interested in funding this.
Cannot extrapolate from high income settings
- Need time specific data for each country / region / hospital
- Calculations require recurrent AND capital estimates but little use of formal business methods to do this

Need costing studies of the whole 'pathway' NOT just the hospital
therapeutic geographies and patient dynamics are very unstable



 KING'S HEALTH PARTNERS


Integrated Cancer Centre

Audrey Tsunoda. *Migration of breast cancer patients in Brazil*

Developing institutions for cancer care in low-income and middle-income countries *Lancet Oncology* 2018 8: 395-406



 KING'S HEALTH PARTNERS
Integrated Cancer Centre



 KING'S HEALTH PARTNERS

Integrated Cancer Centre

CASE FOR INVESTMENT And Value




KING'S HEALTH PARTNERS
Integrated Cancer Centre

**But bare in mind what you think should be invested in is
probably not what others do**



 KING'S HEALTH PARTNERS
Integrated Cancer Centre

Divergent, unstable health priorities: where does breast cancer fit in?



THE LANCET Oncology

Volume 38 Issue 11 September 2015 www.thelancet.com

Global cancer surgery: delivering safe, affordable, and timely cancer surgery




"Surgery is essential for global cancer care...[and] must be at the heart of global and national cancer control planning."



@GSCommission


Global Surgery 2030: evidence and solutions for achieving health, welfare and economic development

THE LANCET Commission on Global Surgery



India: cancer burden and health systems

Published: April 12, 2014



India: Towards Universal Health Coverage

Published: January 11, 2011

Executive Summary

This Series of papers on India's path to full health coverage reveals that a failing health system is perhaps India's greatest predicament. The papers in this Series reveal the full extent of opportunities and difficulties in Indian healthcare, by examining infectious and chronic diseases, availability of treatments and doctors, and the infrastructure to bring about universal health care by 2020. The Series brings together a rapidly growing body of evidence to show that Indian health is in crisis. As the country with the largest democracy in the world, India is well positioned to put health high on the political agenda.



 KING'S HEALTH PARTNERS
Integrated Cancer Centre

Investment to scale up: need country specific cases building on already validated methods using real data e.g. HERO in RXT




 KING'S HEALTH PARTNERS

Pascale Ondo, et al. African J Lab Med 2017 (6): a578

Integrated Cancer Centre

Value: formal mechanisms for health technology assessment
Highly specialised and most LMIC do not have this BUT will need it




Need to engage external expertise e.g. IDSI (www.idsihealth.org)


EBM, HTA, and CER: Clearing the Confusion *Milbank Q.* 2010 June; 88(2): 256–276.

AFFORDABILITY

Universal Health Coverage for breast cancer: fantasy island?




What countries spend on their public THE and protection they afford to patients is what matters for affordability




 KING'S HEALTH PARTNERS
Integrated Cancer Centre

For fragile countries, low HDI you do have to question whether, at this time, (breast) cancer care is affordable, if not then it's charitable or ODA




KING'S HEALTH PARTNERS
Integrated Cancer Centre

Financing of domestic healthcare for BC – Byzantine!



Challenge for mobilising domestic resources for BC – need to collect and manage financial resources in a way that unpredictable individual financial risks become predictable, and are distributed among all the members of the pool



KING'S HEALTH PARTNERS
Integrated Cancer Centre

Model	Revenue Source	Groups Covered	Pooling Organization	Care Provision
National Health Service	General revenues	Entire population	Central government	Public providers
Social Health Insurance	Payroll taxes	Specific groups	Semi-autonomous organizations	Own, public, or private facilities
Community-based Health Insurance	Private voluntary contributions	Contributing members	Non-profit plans	NGOs or private facilities
Voluntary Health Insurance	Private voluntary contributions	Contributing members	For- and non-profit insurance organizations	Private and public facilities
Out-of-Pocket Payments (including public user fees)	Individual payments to providers		None	Public and private facilities (public facilities)

NHS Systems

Systems financed through general revenues, covering whole population, care provided through public providers

Strengths

- Pools risks for whole population
- Relies on many different revenue sources
- Single centralized governance system has the potential for administrative efficiency and cost control

Weaknesses

- Unstable funding due to nuances of annual budget process
- Often disproportionately benefits the rich
- Potentially inefficient due to lack of incentives and effective public sector management

Free breast cancer care at designated hospitals
(but what about other conditions?)



KING'S HEALTH PARTNERS

Integrated Cancer Centre

Social Health Insurance

**Systems with publicly mandated coverage for designated groups,
financed through payroll contributions, semi-autonomous
administration, care provided through own, public, or private facilities**

Strengths

- As a 'benefit' tax, there may be more 'willingness to pay'
- Removes financing from annual general government appropriations process
- Generally provides covered population with access to a broad package of services

Weaknesses

- Poor are often excluded unless subsidized by government
- Payroll contributions can reduce competitiveness and lead to higher unemployment; earmarking removes flexibility
- Can be complex and expensive to manage, which is particularly problematic for LICs and some MICs
- Can lead to cost escalation unless effective contracting mechanisms are in place
- Often provides poor coverage for preventive services and chronic conditions

Often associated with choice of provider (but this assumes information symmetry) and furthermore that this covers real costs.

Need to understand how social insurance systems do and do not work in each country – DO NOT assume they can and will cover breast cancer care

- Ensure that public health purchasers have the mandate and accountability to purchase high-quality services for the population with financial protection
(Ghana's legislation and annual NHIA report to Parliament on equity)
- Strengthen integrated service delivery networks
(Thailand district health system as the contracting entity)
- Create the right balance of autonomy and accountability for providers to respond to incentives and serve the public interest
(Sri Lanka "do more with less")
- Use information to understand, motivate and improve provider performance
(Argentina Plan Sumar)
- Create the right incentives through properly aligned provider payment systems
(Argentina Plan Sumar; Thailand UC Scheme)

MUST have regulation of both private and public sector care – supply and demand side



- Myth of private and public partnership– rent seeking at every level
- Quality and appropriateness of care
- Pay differentials
- Technology overuse
- Massive problem with unregulated private market – **cancer is THE most lucrative area in healthcare**

 KING'S HEALTH PARTNERS
Integrated Cancer Centre

UHC in Turkey: enhancement of equity
Lancet 2013, 382: 65-99

- **We are awash with economic *Kommentariat*, modelling and aggregation that is high-income dominated and barely reflects the ground reality for financing cancer care.**
- Breast cancer financing as a Trojan horse - advocacy for public THE, for building surgery, pathology etc.
- Need detailed ground assessments, and detailed financial plans with stratification of funding and revenue sources.
- Need more detailed studies of economics of BC across all your settings



Sullivan R, Pramesh CS, Booth C. Cancer patients need better care, not just more technology.
Nature 2017 549: 325-328

Integrated Cancer Centre

